[1] Leonhard SE, Mandarakas MR, Gondim F, et al.Diagnosis and management of GuillainBarré syndrome in ten steps[J]. Nat Rev Neurol,2019,15(11):671683. [2] Wachira VK,Farinasso CM,Silva RB,et al.Incidence of GuillainBarré syndrome in the world between 1985 and 2020: A systematic review[J]. Glob Epidemiol,2023,5: 100098. [3] de Andrade da Silva R,Cremaschi RC,Rebello Pinho JR,et al. GuillainBarré syndromethe challenge of unrecognized triggers[J]. Neurol Sci,2019,40(11): 24032404. [4] CAO Y,GUI M,JI S,et al.Guillain-Barré syndrome associated with myasthenia gravis: Three cases report and a literature review[J]. Medicine, 2019,98(47): e18104. [5] 中国吉兰-巴雷综合征诊治指南2024[J].中华神经科杂志,2024,9(57):936-944. [6] 孙美,高甜文,程虹,等. ICU获得性肌无力的影响因素及肌电图改变[J].临床神经病学杂志, 2025,38(6):432-437. [7] 曾敏,唐雪梅,陈静,等.丙种球蛋白治疗的吉兰-巴雷综合征患者预后影响因素分析[J].安徽医学, 2022,43(3):333-336. [8] Zhu W, Li K,Cui T,et al.Detection of anti-ganglioside antibodies in Guillain-Barré syndrome[J]. Ann Transl Med, 2023,11(7):289. [9] Kaida,Kenichi,M. Kanzaki,et al. Anti-ganglioside complex antibodies associated with severe disability in GBS[J]. J Neuroimmunol, 2007,182(1-2):212-218. [10] van den Berg B,Walgaard C,Drenthen J, et al. Guillain-Barré syndrome: pathogenesis,diagnosis,treatment and prognosis[J]. Nat Rev Neurol, 2014, 10: 469-482. [11] Kaida K,Ariga T,Yu RK.Antiganglioside antibodies and their pathophysiological effects on Guillain-Barré syndrome and related disorders--a review[J]. Glycobiology, 2009,19(7):676-692. [12] 赵良松,罗超.肠内营养对重症急性胰腺炎大鼠肠黏膜免疫屏障的影响及机制研究[J].中国免疫学杂志,2026,42(6):1348-1353. [13] 吴章薇,赵军,李冰洁,等. 以手术为诱因的重型吉兰巴雷综合征临床特点和预后分析[J]. 中国神经精神疾病杂志,2017,43(5):300-303. [14] 王莹. 空肠弯曲菌cheY,ciaB,dnaJ,cfrA基因的克隆及其真核表达载体的构建[D]. 河北医科大学,2011. |